Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Coping strategies therapy significantly improves dementia carers' mental health, quality of life

  • Behavioral flexibility impaired after exposure to oxycodone

  • New insights link Fragile X Syndrome, Autism Spectrum Disorders

  • Rapid response for inflammation control in songbirds' brains could lead to therapies in humans

  • Epidemic spreading and neurodegenerative progression

  • Tapeworm found living inside a patient's brain: Worm removed and sequenced

  • Mental disorders due to permanent stress?

  • Brain injuries in mice treated using bone marrow stem cells, antioxidants

  • Repetitive transcranial magnetic stimulation studied for stroke rehab

  • Study of Lou Gehrig's disease shifts 'origin' focus to brain's motor neurons

  •